This week’s coverage highlights a bifurcated market: AI-driven re‑rating and platform optionality on one side, and defensive, cash‑generative healthcare and diagnostics on the other. Across 23 company pieces, analysts weigh valuation cushions against execution and margin risks, producing a broadly balanced outlook.